Antiepileptic Drugs Tied to Incident Parkinson Disease
Magnitude of the association increased with the number of antiepileptic drugs prescribed
Diagnosis & Disease Information
Deferiprone Not Beneficial for Newly Diagnosed Parkinson Disease
Greater decrease seen in nigrostriatal iron content with deferiprone, but more patients have symptom progression leading to initiation of dopaminergic therapy
Novel Formulation of Carbidopa/Levodopa Under Review for Parkinson Disease
The NDA is supported by data from the phase 3 RISE-PD trial.
ENT-01 Safe, Improves Constipation in Patients With Parkinson Disease
Improvement seen in weekly complete spontaneous bowel movement rate and in secondary end points
DaTscan Approved for Use in Patients With Suspected Lewy Body Dementia
DaTscan is a radioactive diagnostic agent that works by binding reversibly to the human dopamine transporter (DaT) in the brain.
October 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in October 2022 for investigational products in development.
MPR Weekly Dose Podcast #134
Bivalent COVID-19 booster vaccines for children; wearable device to help treat fluid overload in adults with chronic heart failure; real-world data insights into molnupiravir efficacy; vaccine for the third trimester of pregnancy to prevent pertussis; and an FDA update on apomorphine infusion in Parkinson disease.
FDA Needs More Data Before Deciding on Apomorphine Infusion Device
SPN-830 provides a continuous subutaneous infusion of apomorphine through an infusion pump
Acupuncture May Ease Anxiety in Patients With Parkinson Disease
Patients randomly assigned to eight weeks of treatment with either real or sham acupuncture
Monoclonal Antibodies No Better Than Placebo for Early Parkinson Disease
Two studies show lack of benefit in primary or secondary end points with cinpanemab or prasinezumab versus placebo
